Last updated on April 16, 2014 at 21:24 EDT

Hovione: EPO Grants a New Inhaler Patent

September 11, 2013

LISBON, Portugal, September 11, 2013 /PRNewswire/ –

Hovione announced today that the European Patent Office has granted a patent for
Hovione’s XCaps, a dry powder inhaler (DPI).

XCaps addresses a pulmonary inhalation market need for a very inexpensive device which
combines high efficiency in powder dispersion with ease of use. Lung fractions in excess
of 70% have been achieved, from a device which only requires two steps to inhalation and
which only has two components plus a dust cover. This makes XCaps highly suited for
inhalation applications where minimal training of patients is desirable and has the
versatility to treat almost all pulmonary diseases, including asthma, COPD as well as
infection, which typically require very large dose delivery.

XCaps follows on the heels of another successful Hovione DPI, TwinCaps(R), which was
developed specifically for an influenza application and is licensed to Daiichi Sankyo and
Biota for this application.

Hovione is offering XCaps as a part of its inhalation device portfolio, allowing its
integration with a drug product development program, allowing business partners to take
their candidate drugs from the API stage all the way to the unit dose, with a single

Peter Villax, Vice-President and co-inventor of the device, said “We give our
customers an edge in speed of development because we are perhaps the only independent
company developing DPIs with expertise in every aspect of the inhaled drug development
process. Granting of the European Patent on the XCaps inhaler, within 30 months after
initial filing, underpins Hovione’s capabilities in innovation and intellectual property
management, to successfully design, develop and deliver innovative products, namely, a
quality inhalation device, addressing a market need”.

“The XCaps addresses a gap for a simple, easy to use, cost effective, multiple use,
capsule based inhalation device. This allows our business partners to take advantage of
additional patent protection for their inhalation drug product and effective drug product
life cycle management” said Goncalo Andrade, Business Development Manager.

Hovione is currently executing inhaled drug development projects for multiple
pharmaceutical companies, involving API process development, particle engineering,
formulation and clinical supplies and is looking for partners willing to incorporate the
XCaps into their inhalation drug development.

About Hovione. Hovione is a global company with over 50 years’ experience in Active
Pharmaceutical Ingredient and Drug Product Intermediate development and compliant
manufacture. With four FDA inspected sites in the U.S., China, Ireland, and Portugal, the
company focuses on the most demanding customers in the most regulated markets. Hovione
offers integrated API, particle design, formulation development and GMP manufacturing. In
the inhalation area, Hovione is the only independent company offering such a broad range
of services.

More about XCaps at http://www.hovione.com/inhale

        Contacts at Hovione:
        Goncalo Andrade, PhD                Isabel Pina
        Business Development Manager        Director Corporate Communications
        gandrade@hovione.com                ipina@hovione.com
        +351-219-847-619                    +351-21-982-9362


SOURCE Hovione

Source: PR Newswire